Crinetics Pharmaceuticals (CRNX)

• Market cap: $3.88B
• 1 day: -0.05%
• 5 days: 5.93%
• 1 month: -4.76%
• 3 months: -15.91%
• 6 months: -20.1%
• Year to date: -21.29%
• 1 year: 24.68%
• 5 years: 106.28%
• 10 years: 50.06%
• Sector: Healthcare
• Industry: Biotechnology

About: Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Employees: 594